NCT02324439View on ClinicalTrials.gov

Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2021

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
DRUG

Omega Nutrition cold-milled flaxseeds

Patients who are currently in clinical remission will receive a daily 20g dose of cold milled flaxseed as a dietary supplement to determine if this intervention prolongs clinical remission.

Trial Locations (1)

62702

Southern Illinois University School of Medicine, Springfield

All Listed Sponsors
lead

Southern Illinois University

OTHER

NCT02324439 - Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | Biotech Hunter | Biotech Hunter